Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Laboratorios Farmaceuticos Rovi, S.A.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Laboratorios Farmaceuticos Rovi, S.A.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Laboratorios Farmaceuticos Rovi, S.A.
  • With an enterprise value anticipated at 3.82 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Rating Financials

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Laboratorios Farmaceuticos Rovi, S.A. SectorAustria

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
342.25Cr
BBB
98TCr
A
55TCr
BBB
38TCr -
AA
- -
32TCr
AA
27TCr
A
27TCr
AAA
19TCr
A
18TCr
A
15TCr
AA
Average 32.97TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. ROVI Stock
  5. Ratings Laboratorios Farmaceuticos Rovi, S.A.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!